Related Experiment Video
Updated: Dec 8, 2025
05:33
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
10.7K
Proteolysis targeting chimeras (PROTACs) in cancer therapy
Alberto Ocaña1,2,3, Atanasio Pandiella4,5
1Experimental Therapeutics Unit, Medical Oncology Department, Hospital Clínico San Carlos, and IdISSC, Madrid, Spain. alberto.ocana@salud.madrid.org.
Journal of Experimental & Clinical Cancer Research : CR
|September 16, 2020
Summary
Proteolysis targeting chimeras (PROTACs) harness the cell's protein degradation system to eliminate disease-causing proteins. This review explores the molecular mechanisms and clinical potential of PROTACs in targeted protein degradation therapies.
Area of Science:
- Molecular medicine
- Biochemistry
- Drug discovery
Background:
- Targeted protein degradation is a novel therapeutic strategy.
- Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules.
- PROTACs recruit E3 ubiquitin ligases to target proteins.
Purpose of the Study:
- To review the molecular mechanisms of PROTACs.
- To highlight recent advancements in PROTAC technology.
- To discuss the clinical translation of PROTAC-based therapies.
Main Methods:
- Review of existing literature on PROTACs.
- Analysis of PROTAC molecular mechanisms.
- Discussion of preclinical and clinical developments.
Main Results:
- PROTACs induce ubiquitination and proteasomal degradation of target proteins.
- Recent developments show promise for various diseases.
- Clinical trials are underway for several PROTACs.
Conclusions:
- PROTACs represent a significant advancement in targeted protein degradation.
- The technology holds great potential for treating diseases, including cancer.
- Further research and clinical studies are crucial for realizing the full therapeutic potential.
Related Concept Videos
02:57Targeted Cancer Therapies
8.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.4K
02:50Combination Therapies and Personalized Medicine
5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
01:27Tumor Immunotherapy
1.4K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.4K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.6K
02:18The Proteasome
9.8K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.8K
02:53Conservative Site-specific Recombination and Phase Variation
6.5K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.5K